Screener
BridgeBio Pharma BBIO Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.
The source filing: BridgeBio Pharma’s 10-Q, filed May 2, 2024.
- Filed
- May 2, 2024
- Fiscal quarter
- Q1 FY2024
- Calendar quarter
- Q1 2024
- Accession
- 0000950170-24-052165
| Line item | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 |
|---|---|---|
| Decrease in cash and cash equivalents resulting from deconsolidation of PellePharm | — | (503) |
| Net cash provided by investing activities | 22,753 | 12,298 |
| Financing activities: | ||
| Proceeds from term loan under Financing Agreement | 450,000 | — |
| Issuance costs and discounts associated with term loan under Financing Agreement | (12,254) | — |
| Repayment of term loan under Loan and Security Agreement | (473,417) | — |
| Proceeds from issuance of common stock through public offerings, net | 315,254 | 143,016 |
| Proceeds from BridgeBio common stock issuances under ESPP | 2,364 | 1,809 |
Cover / Front Matter
FAQ
- What is BridgeBio Pharma's debt issuance proceeds?
- BridgeBio Pharma (BBIO) reported debt issuance proceeds of $450M in Q1 2024.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about BridgeBio Pharma's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude